Phase 1, Open Label Trial to Evaluate the Safety and Immunogenicity of PAN-301-1 in Cancer Patients

Trial Profile

Phase 1, Open Label Trial to Evaluate the Safety and Immunogenicity of PAN-301-1 in Cancer Patients

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Oct 2018

At a glance

  • Drugs SNS 301 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; First in man
  • Sponsors Sensei Biotherapeutics
  • Most Recent Events

    • 19 Oct 2018 Results published in the Sensei Biotherapeutics Media Release
    • 09 Oct 2018 According to a Sensei Biotherapeutics media release, data from this study will be presented at the European Society for Medical Oncology (ESMO) 2018 Congress and at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
    • 05 Jun 2018 Results (n=12) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top